- Cancer Types
Information about risk, prevention, screening, symptoms, diagnosis, treatment, and support for all cancers Cancer A to Z - Cancer Treatment
Cancer Treatment
Information about cancer treatment, including surgery, chemotherapy, radiation therapy, clinical trials, proton therapy, complementary medicine, and cutting edge technologies.
- Risk and Prevention
- Cancer Drugs
- Support
Support
Ways for cancer patients and caregivers to cope with cancer, side effects, nutrition, general cancer support issues, grief/end of life issues, and shared survivor's experiences.
- Healthcare Professionals
- Clinical Trials
My Patient Treatment Binder
OncoLink Blogs
What's My Cancer Risk?
OncoPilot: Navigating Your Cancer Journey
Community Events Calendar
OncoLink eNews
Abramson Cancer CenterMonday, December 10 - Scientific Presentations
|
A Randomized Trail of Fludarabine and Mitoxantrone Plus Rituximab Versus CHOP Plus Rituximab as First-Line Treatment in Patients with Follicular Lymphoma
Presenter: Pier Luigi Zinzani Presenter's Affiliation: Type of Session: Scientific Background Fludarabine plus Mitoxantrone (FM) is an effective combination chemotherapy regimen for the treatment of follicular lymphoma. In this study, FM is... |
|
|
Acute Myeloid Leukemia in Adolescents and Young Adults (AYAs): A Comparison of Outcomes Between Patients Treated on Childhood or Adult Protocols
Presenter: William G. Woods Presenter's Affiliation: Emory University, Atlants, GA and Children's Cancer Group, Arcadia, CA Type of Session: Scientific Background Children with AML are frequently treated with more aggressive regimens than... |
|
|
Air Travel, Prothrombotic Mutations and Venous Thrombosis: The MEGA Study
Presenter: Frits R. Rosendaal Presenter's Affiliation: Leiden University Medical Center, Leiden, Netherlands Type of Session: Scientific Background Contradictory reports on air travel and deep venous thrombosis (DVT) risk have documented... |
|
|
CHEOP (Chop + Etoposide): the New Standard Regimen for Younger Patients with Low Risk (Low LDH) Aggressive Non-Hodgkin's Lymphoma (NHL)
Presenter: Michael G. Pfreundlschuh Presenter's Affiliation: Type of Session: Scientific Background Low Risk (normal LDH)aggressive NHL has classically been treated with CHOP chemotherapy given on a 21 day dosing schedule. The objective... |
|
|
CHOP Alone Compared to CHOP Plus Radiotherapy for Early Stage Aggressive Non-Hodgkin's Lymphomas: Update of the Southwest Oncology Group (SWOG) Randomized Trial
Presenter: T.P. Miller Presenter's Affiliation: Arizona Cancer Center, Tuscon, AZ Type of Session: Scientific Background In 1998, SWOG study 87-36 reported the results of a randomized trial comparing 8 cycles of CHOP chemotherapy with 3 cycles of... |
|
|
Concurrent Fludarabine and Total Body Irradiation (F-TBI) for Patients with Advanced Relapsed, Refractory, or Resistant Indolent Non-Hodgkin's Lymphoma (NHL): A Phase I Trial.
Presenter: David Eilender Presenter's Affiliation: Wayne State University Type of Session: Poster Background Both chemotherapy (CHT) and radiation therapy (RT) are used in the treatment of non-Hodgkin's lymphoma (NHL). It is well known that... |
|
|
Cytotoxicity of Mevastatin and Other Cholesterol Modulators in Acute Myeloid Leukemia
Presenter: Henry Y. Li Presenter's Affiliation: Fred Hutchinson Cancer Research Center Type of Session: Scientific Background The mevalonate pathway is essential to cell survival, producing essential sterols, ubiqinones, retinoids and... |
|
|
Early Restaging Positron Emmision Tomography (PET) with 18F-Fluorodeoxyglucose (18FDG)Predicts Outcome in Patients with Aggressive Non-Hodgkin's Lymphoma (NHL)
Presenter: Karoline Spaepen Affiliation: Leuven, Belgium Background Positron Emission Tomography (PET) with FDG (a radiolabeled sugar molecule) is a nuclear medicine study that is able to detect areas of active cancer by showing areas of... |
|
|
Final Report of E1484: CHOP vs CHOP + Radiotherapy (RT) for Limited Stage Diffuse Aggressive Lymphoma
Presenter: Sandra J. Horning Presenter's Affiliation: Stanford University Type of Session: Scientific Background The objectives of this study were threefold: to determine the rate of complete response (CR) to, and toxicity of, eight cycles of... |
|
|
Gastric MALT Lymphomas Prospective LY03 Randomized Cooperative Trial: Preliminary Results of the Molecular Follow-up
Presenter: F. Bertoni Presenter's Affiliation: Barts and The London, London Type of Session: Scientific Background Gastric MALT lymphoma is most commonly treated with antibiotic therapy directed at H. Pylori infection. Previous studies have... |
|
|
High Levels of Soluble CD20 (sCD20) in patients with Non-Hodgkin's Lymphoma (NHL): Correlation with Clinical Behavior and Contrast with Patients with Hodgkin's Disease (HD)
Presenter: M. Albitar Presenter's Affiliation: MD Anderson Cancer Center, Texas Type of Session: Scientific Background CD20 is a Glycoprotein transmembrane receptor found on mature B-cells. Differences in the levels of surface CD20 on B-cells... |
|
|
Multiple Resistance Mechanisms Identified through Studies of Cell Lines Derived from Chronic Myelogenous Leukemia Patients Progressing on STI-571 Therapy
Presenter: Nicholas J. Donato Presenter's Affiliation: MD Anderson Cancer Center Type of Session: Scientific Background STI-571 is known to be an effective inhibitor of the BCR-ABL fusion protein and therefore has become a common treatment for... |
|
|
Requestioning the Role of Prolonged Maintenance Chemotherapy in AML: Randomized Trial by the German AML Cooperative Group Updated.
Presenter: Thomas Buechner Presenter's Affiliation: German AML Cooperative Group Type of Session: Scientific Background The German AML Cooperative Group (GAMLCG) has previously reported a survival advantage to 3 years of montly maintenance... |
|
|
t(11;18) Is a marker for All Stage Gastric MALT Lymphomas That Will Not Respond o H. Pylori Eradication
Presenter: H. Liu Presenter's Affiliation: Universiy College London Type of Session: Scientific Background Eradication of H. Pylori infection leads to complete regression of gastric mucosa associated lymphoid tissue (MALT)lymphoma in greater... |
|
|
The Combination of Low D-Dimer Concentration and Non-High Clinical Probability Score is a Safe Strategy to Exclude Deep Venous Thrombosis
Presenter: Roger E.G. Schutgens Presenter's Affiliation: St. Antonius Hospital, the Netherlands Type of Session: Scientific Background Compression Ultrasonography (CUS) is considered the gold standard for the diagnosis of deep venous thrombosis... |
|
|
Thrive I: Efficacy and Tolerability of the Novel, Oral Direct Thrombin Inhibitor Ximelagatran Compared with Standard Therapy for the Treatment of Acute Deep Venous Thrombosis
Presenter: Sam Schulman Presenter's Affiliation: Karolinska Hospital, Stockholm, Sweden Type of Session: Scientific Background Ximelagatran is an orally available, direct thrombin inhibitor. It is absorbed and converted to its active form,... |
Cancer Types
Bone Cancer
Brain Tumors
Breast Cancer
Carcinoid Tumors
Endocrine System Cancers
Gastrointestinal Cancers
Gynecologic Cancers
Head and Neck Cancers
Leukemia
Lung Cancers
Lymphomas
Myelomas
Pediatric Cancers
Penile Cancer
Prostate Cancer
Sarcomas
Skin Cancers
Testicular Cancer
Thyroid Cancer
Urinary Tract Cancers
OncoLink Vet
Cancer Treatment
Biologic Therapy
Bone Marrow Transplants
Chemotherapy
Clinical Trials
Complementary Medicine
Gene Therapy
General Treatment Concerns
Hormone Therapy
PDT Center
Proton Therapy
Radiation Oncology
Surgical Oncology
Targeted Therapies
Vaccine Therapies
Cancer Support
Caregivers
Hospice Care and Bereavement
Nutrition and Cancer
Sexuality & Fertility
Side Effects
Support
Survivorship
Exercise and Cancer
Cancer Resources
Cancer News
OncoLink University
Nurses' Notes
Conferences
Newly Diagnosed Patients
Causes and Prevention
Legal and Financial Information for Patients
LGBT Resources
NCI Resources
Global Resources
Cancer Resource List
Resources for Young Adults
OncoLink Media Library
OncoLink TV
Book, Music and Video Reviews
Ask the Experts
Brown Bag Chat
Tracy's Corner
About OncoLink
About OncoLink
Giving to OncoLink
Contact Information
Usage Policy
Editorial Board
How to Partner with OncoLink
Link to OncoLink
Mission Statement
